Russell P Rother

Summary

Affiliation: Alexion Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
    Russell P Rother
    Alexion Pharmaceuticals, Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, USA
    Nat Biotechnol 25:1256-64. 2007
  2. ncbi request reprint The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease
    Russell P Rother
    Alexion Pharmaceuticals, Cheshire, Conn 06410, USA
    JAMA 293:1653-62. 2005
  3. ncbi request reprint Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Haematology, Leeds Teaching Hospitals NHS Trust, UK
    Haematologica 90:ECR40. 2005
  4. ncbi request reprint Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Department of Haematology, Leeds Teaching Hospitals National Health Science Trust, Leeds, United Kingdom
    N Engl J Med 350:552-9. 2004
  5. ncbi request reprint Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Blood 111:1840-7. 2008
  6. ncbi request reprint Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX, United Kingdom
    Blood 106:2559-65. 2005
  7. ncbi request reprint The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    N Engl J Med 355:1233-43. 2006
  8. ncbi request reprint Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    Blood 110:4123-8. 2007
  9. ncbi request reprint Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis
    Yuefang Zhou
    Department of Neurology and Psychiatry, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    J Immunol 179:8562-7. 2007
  10. ncbi request reprint A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins
    Marek Jasinski
    Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 103:2827-34. 2004

Collaborators

  • Mark T Gladwin
  • Peter Hillmen
  • Anita Hill
  • Antonio Maria Risitano
  • R A Brodsky
  • J P Maciejewski
  • Lucio Luzzatto
  • Stephen J Richards
  • Susan K Halstead
  • Yuefang Zhou
  • Paul J Tacken
  • Hao Wang
  • Marek Jasinski
  • Jaap J Plomp
  • Peter D Humphreys
  • Jan J Verschuuren
  • Bart C Jacobs
  • Kay Greenshields
  • Femke M P Zitman
  • Hugh J Willison
  • Bendi Gong
  • Feng Lin
  • Henry J Kaminski
  • M Edward Medof
  • Ben Joosten
  • Dalibor Kubelik
  • Gang Chen
  • Dayang Wu
  • Susan J Faas
  • Bertha Garcia
  • I Jolanda M de Vries
  • Robert Zhong
  • Jifu Jiang
  • Weihua Liu
  • Cornelis J A Punt
  • Carl G Figdor
  • Ruurd Torensma
  • Karlijn Gijzen
  • David Gies
  • Gosse J Adema
  • Wen Chao Song
  • Hector Molina
  • Panagiotis Pantazopoulos
  • Nico Van Rooijen
  • Monica Bessler

Detail Information

Publications13

  1. ncbi request reprint Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
    Russell P Rother
    Alexion Pharmaceuticals, Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, USA
    Nat Biotechnol 25:1256-64. 2007
    ....
  2. ncbi request reprint The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease
    Russell P Rother
    Alexion Pharmaceuticals, Cheshire, Conn 06410, USA
    JAMA 293:1653-62. 2005
    ..A growing list of clinical manifestations attributed to hemoglobin release in a variety of acquired and iatrogenic hemolytic disorders suggests that hemolysis and hemoglobinemia should be considered as a novel mechanism of human disease...
  3. ncbi request reprint Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Haematology, Leeds Teaching Hospitals NHS Trust, UK
    Haematologica 90:ECR40. 2005
    ..Complement inhibition has been sustained for over 2 years and results in resolution of intravascular hemolysis and amelioration of symptoms associated with smooth muscle contractions...
  4. ncbi request reprint Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Department of Haematology, Leeds Teaching Hospitals National Health Science Trust, Leeds, United Kingdom
    N Engl J Med 350:552-9. 2004
    ..We tested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, in patients with PNH...
  5. ncbi request reprint Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Blood 111:1840-7. 2008
    ..This trial is registered at http://clinicaltrials.gov as NCT00130000...
  6. ncbi request reprint Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX, United Kingdom
    Blood 106:2559-65. 2005
    ..Eculizumab continued to be safe and well tolerated, and all patients completed the study. The close relationship between sustained terminal complement inhibition, hemolysis, and symptoms was demonstrated...
  7. ncbi request reprint The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    N Engl J Med 355:1233-43. 2006
    ..We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH)...
  8. ncbi request reprint Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    Blood 110:4123-8. 2007
    ..001). These results show that eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH. This study is registered at http://clinicaltrials.gov (study ID no. NCT00122317)...
  9. ncbi request reprint Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis
    Yuefang Zhou
    Department of Neurology and Psychiatry, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    J Immunol 179:8562-7. 2007
    ..The results argue that targeting C5 may warrant testing in MG patients and that this approach may be particularly valuable for myasthenic crisis...
  10. ncbi request reprint A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins
    Marek Jasinski
    Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 103:2827-34. 2004
    ..Future investigations will show whether this novel pathway of PIGA- RBC destruction identified in mice may also operate in patients with PNH...
  11. ncbi request reprint Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine
    Hao Wang
    Multi Organ Transplant Program, London Health Sciences Centre, London, Ontario, Canada
    Transplantation 79:1121-7. 2005
    ....
  12. ncbi request reprint Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody
    Paul J Tacken
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Blood 106:1278-85. 2005
    ..This identifies DC-SIGN as a promising target molecule for DC-based vaccination strategies...
  13. doi request reprint Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model
    Susan K Halstead
    University of Glasgow, Division of Clinical Neurosciences, Glasgow Biomedical Research Centre, Glasgow, UK
    Brain 131:1197-208. 2008
    ....